lifileucel
Feb 26, 2024
Iovance’s Breakthrough: Amtagvi Paves the Way for Cell Therapies in Solid Tumors
The category of T-cell therapy, which revolutionized the management of specific blood cancers, has now extended its impact to solid tumor treatment with the approval from the FDA of a groundbreaking immunotherapy pioneered by Iovance Biotherapeutics. Known as Amtagvi or lifileucel, this medication marks the debut o...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
